Securities Code: 300289 Stock Abbreviation: Leadman Announcement No.: 2026-037
Beijing Leadman Biochemistry Co., Ltd.
Announcement on Amendments to the Report on Major Asset Purchase (Draft)
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
Beijing Leadman Biochemistry Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") intends to acquire 235,040,700 shares of Beijing Leadman Xiangrui Biological Products Co., Ltd. (hereinafter referred to as "Xiangrui Bio") from Hainan Baimai Investment Co., Ltd., Hainan Preshine Bioscience Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Xiangrui Bio"), representing 61.50% of the issued shares of Xiangrui Bio (hereinafter referred to as the "Transaction").
On November 13, 2025, the Company disclosed the "Report on Major Asset Purchase (Draft)" ("Restructuring Report") and related documents. For details, please refer to the relevant announcements published by the Company on the CNINFO website (http://www.cninfo.com.cn), the designated information disclosure media of the China Securities Regulatory Commission.
On January 9, 2026, the Company responded to the "Inquiry Letter on Restructuring" issued by the Shenzhen Stock Exchange (hereinafter referred to as the "SZSE"), and disclosed the "Announcement on Responding to the Inquiry Letter on Restructuring from Shenzhen Stock Exchange".
On June 12, 2026, the Company held the twelfth meeting of the sixth Board of Directors and deliberated and approved the "Proposal on the Adjustment of the Transaction Plan Not Constituting a Major Adjustment". It is proposed to adjust the transaction consideration and performance commitment related to this transaction. Regarding the above matters, the Company has revised the "Report on Major Asset Purchase (Draft) (Revised Draft)" of Beijing Leadman Biochemistry Co., Ltd. to supplement, revise, and improve it, with the revised and supplemented content marked in bold and italics.
The main revised content of the Report on Major Asset Purchase (Draft) (Revised Draft) is as follows: